ACON ACLARION INC

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024

BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion’s CEO, Brent Ness, has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15th, 2024, at 2:00 p.m. E.T.

Maxim senior analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit .

Investor Contacts:

Kirin M. Smith

PCG Advisory, Inc.

646.823.8656

Media Contacts:

Jodi Lamberti

SPRIG Consulting

612.812.7477



EN
10/10/2024

Underlying

ACONACLARION INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ACLARION INC

 PRESS RELEASE
Free
ACON ACLARION INC

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNET...

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients MAGNETOM Flash is a Peer-to-Peer Magazine Published by Siemens to Showcase Advancing Technologies in the MRI Space The RSNA Edition Coincides With the Annual Meeting of the Radiology Society of North America (RSNA) BROOMFIELD, Colo., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is le...

November 21, 2024 1 EN
 PRESS RELEASE
Free
ACON ACLARION INC

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion’s CEO, Brent Ness, has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesda...

October 10, 2024 1 EN
 PRESS RELEASE
Free
ACON ACLARION INC

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Mod...

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help Stratify MC Patients to Potentially Inform Better Treatment Decisions for cLBP Patients Results Presented at the 50th International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting 2024 BROOMFIELD, CO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Co...

September 27, 2024 1 EN
 PRESS RELEASE
Free
ACON ACLARION INC

Aclarion Provides Corporate Update on Nociscan AI Technology Milestone...

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions Progressing with proven path toward standard of care addressing chronic low back pain, the largest expenditure in US healthcare costing Americans an estimated $134 Billion annually More than $50 Million has been invested in the promising Aclarion AI platform that aids physicians in identification of painful discs Technology protected by 23 issued US patents, 17 issued international pate...

September 12, 2024 1 EN
 PRESS RELEASE
Free
ACON ACLARION INC

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled Trial in Norway Comparing Lumbar Interbody Fusion Surgery With Multidisciplinary Rehabilitation LIFEHAB Joins the NIH and Rome in Selecting Nociscan as a Technology to Help Determine Which Discs to Treat and the Technology’s Role in Selecting Optimal Treatment Options BROOMFIELD, CO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion,...

September 10, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch